Assessment of treatment response to immunotherapy in melanoma patients with pathogenic mutations of NRAS, BRAF, CDKN2A and P53.

作者
Thomas DeLeon,Benjamin R. Kipp,Blake Langlais,Thomas J. Flotte,Jennifer L. Winters,Heidi Kosiorek,Richard W. Joseph,Svetomir N. Markovic,Roxana Dronca,Matthew S. Block,Robert R. McWilliams,Lisa A. Kottschade,Mitesh J. Borad,Kandelaria M. Rumilla,Jesse S. Voss,Alan H. Bryce
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (15_suppl): e21057-e21057 被引量:1
标识
DOI:10.1200/jco.2017.35.15_suppl.e21057
摘要

e21057 Background: BRAF, NRAS, CDKN2A and P53 mutations are commonly observed pathogenic mutations in cutaneous melanoma. The influence of mutations such as BRAF, NRAS, CDKN2A and P53 on treatment response in the PD1 inhibitor era has not been well defined. Methods: This study included patients with melanoma with a cutaneous or unknown primary. All patients had genomic profiling with the Mayo Clinic 50-gene solid tumor mutation panel. Treatment response to first line immunotherapy with PD1, CTLA-4, or combination PD1/CTLA-4 inhibitors were assessed by response rate and time-to-progression (TTP) rate at 12 months. Each patient outcome was stratified by non-mutually exclusive gene mutation status into BRAF, NRAS, P53, CDKN2A, or quadruple negative (N4) groups. Results: Genomic profiling was performed on 208 patients, of whom 102 received first line immunotherapy. Most patients received a PD1 inhibitor (n = 62), followed by CTLA-4 inhibitor (n = 34), and combination therapy (n = 6). A trend towards improved outcomes was observed in CDKN2A and BRAF mutated patients with worse outcomes noted in P53, N4, and NRAS patients. The percent without progression at 12 months were BRAF 52.2%, CDKN2A 58.2%, NRAS 30.5%, P53 37.7%, and N4 26.7% (see table below). Response rates were BRAF 46.4%, CDKN2A 38.5%, NRAS 22.2%, P53 40.0%, and N4 33.3%. Conclusions: There is a trend towards improved outcomes with immunotherapy in BRAF and CDKN2A mutated patients while P53, NRAS and N4 patients have inferior outcomes. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
浅浅发布了新的文献求助10
1秒前
情怀的应助被sinalpha10采纳,获得10
1秒前
凡心所向完成签到,获得积分10
2秒前
2秒前
2秒前
栗子发布了新的文献求助10
3秒前
3秒前
1122完成签到,获得积分10
3秒前
3秒前
3秒前
Lilyan完成签到,获得积分10
4秒前
常富育发布了新的文献求助10
4秒前
ramia完成签到 ,获得积分10
4秒前
易福林发布了新的文献求助10
5秒前
忘先知关注了科研通微信公众号
5秒前
More的应助被整齐成仁采纳,获得10
5秒前
lzd发布了新的文献求助10
7秒前
庾磬完成签到,获得积分10
7秒前
领导范儿的应助被开心德地采纳,获得10
8秒前
8秒前
龙江游侠完成签到,获得积分10
8秒前
IVY发布了新的文献求助10
8秒前
淡定的凡蕾完成签到,获得积分10
9秒前
大麦古完成签到,获得积分10
9秒前
123发布了新的文献求助10
10秒前
lzd完成签到,获得积分10
11秒前
搜集达人的应助被哈哈哈哈采纳,获得10
11秒前
亮子完成签到,获得积分10
12秒前
12秒前
花陌发布了新的文献求助30
12秒前
14秒前
14秒前
14秒前
wanci的应助被研友_89e5G8采纳,获得10
14秒前
fdawn完成签到,获得积分10
14秒前
14秒前
14秒前
15秒前
佳丽完成签到,获得积分0
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189181
求助须知:如何正确求助?哪些是违规求助? 9576621
关于积分的说明 21848919
捐赠科研通 7787172
什么是DOI,文献DOI怎么找? 3435490
关于科研通互助平台的介绍 2559732
邀请新用户注册赠送积分活动 2482468